The different disease-modifying therapies (DMTs) and immunomodulating treatments used in the management of MS include interferon beta (IFN-β), glatiramer acetate (GA), natalizumab, fingolimod, mitoxantrone, teriflunomide, dimethyl fumarate, alemtuzumab, daclizumab, and ocrelizumab. This evidence concerns the gene IFNB1 and myeloid sarcoma.